52468-60-7

Basic information

• Product Name: Flunarizine
• Synonyms: (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine;(e)-piperazin;1-[Bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]piperazine;Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-;Sibelium;Fluarizine;1-[Bis(4-fluorophenyl)methyl]-4-[(E)-3-phenyl-2-propenyl]piperazine;FLUNARIZINE
• CAS NO: 52468-60-7
• Molecular Formula: C₂₆H₂₆F₂N₂
• Molecular Weight: 404.49
• EINECS: 257-937-5
• Mol File: 52468-60-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 511.3 °C at 760 mmHg
• Flash Point: 263 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 1.43E-10mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: 2-8°C
• PKA: 6.99±0.10(Predicted)
• CAS DataBase Reference: Flunarizine(CAS DataBase Reference)
• NIST Chemistry Reference: Flunarizine(52468-60-7)
• EPA Substance Registry System: Flunarizine(52468-60-7)

Safety Data

• Hazardous Substances Data: 52468-60-7(Hazardous Substances Data)

Usage

Uses

Vasodilator.

Therapeutic Function

Vasodilator

World Health Organization (WHO)

Flunarizine, an antihistaminic and vasodilator agent, was introduced into medicine in 1970. It is indicated for the treatment of central and peripheral vascular disorders. However, its effectiveness in these conditions has not been convincingly demonstrated, and its use has been associated with adverse reactions involving the central nervous system, including extrapyramidal disturbances and depression. This has led several regulatory authorities to restrict the approved indications for products containing flunarizine.

InChI:InChI=1/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2

Upstream product

• 104-55-2 3-phenyl-propenal 
• 75145-31-2 sodium (E)-1-hydroxy-3-phenylprop-2-ene-1-sulfonate 
• 27469-60-9 1-(4-fluorophenyl)methyl-piperazine 
• 104-54-1 3-Phenylpropenol 
• 27064-94-4 4,4'-difluorobenzhydryl chloride 
• 18903-01-0 1-(3-phenyl-2-propenyl)piperazine 
• 18903-01-0 trans-1-cinnamylpiperazine 
• 352-34-1 4-fluoro-1-iodobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 100-59-4 phenylmagnesium chloride 
• 100-58-3 phenylmagnesium bromide 
• 369-57-3 benzenediazonium tetrafluoroborate 
• 1522375-84-3 1-[bis(4-fluorophenyl)methyl]-4-(2,2-dimethoxyethyl)piperazine 
• 1522375-87-6 1-(4,4’-difluorophenylmethyl)-4-(2-acetaldehyde)piperazine 

Relevant articles and documents

Fe-catalyzed synthesis of flunarizine and its (Z)-isomer

-

A Simple, Broad-Scope Nickel(0) Precatalyst System for the Direct Amination of Allyl Alcohols

The preparation of allylic amines is traditionally accomplished by reactions of amines with reactive electrophiles, such as allylic halides, sulfonates, or oxyphosphonium species; such methods involve hazardous reagents, generate stoichiometric waste streams, and often suffer from side reactions (such as overalkylation). We report here the first broad-scope nickel-catalysed direct amination of allyl alcohols: An inexpensive NiII/Zn couple enables the allylation of primary, secondary, and electron-deficient amines without the need for glove-box techniques. Under mild conditions, primary and secondary aliphatic amines react smoothly with a range of allyl alcohols, giving secondary and tertiary amines efficiently. This “totally catalytic” method can also be applied to electron-deficient nitrogen nucleophiles; the practicality of the process was demonstrated in an efficient, gram-scale preparation of the calcium antagonist drug substance flunarizine (Sibelium).

ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN

The invention generally relates to adenylyl cyclase inhibitor compounds and methods for treating neuropathic or inflammatory pain by using those compounds.